Whitehawk Therapeutics(NASDAQ) AADI

Whitehawk Therapeutics, Inc. makes new treatments to fight cancer more precisely. The company helps patients with solid tumors through advanced medicine. These medicines target specific markers on cancer cells to deliver drugs directly.

The Next Generation of Cancer Care

• HWK-007: Lead antibody-drug conjugate (ADC) targeting Protein Tyrosine Kinase 7 (PTK7) for solid tumors.
• HWK-016: ADC therapy targeting Mucin 16 (MUC16) specifically for the treatment of cancers of female origin.
• HWK-206: Investigational drug targeting Seizure-related Protein 6 (SEZ6) for small cell lung cancer and neuroendocrine tumors.
• ADC Platform: Technology that links antibodies to drug payloads to target cancer cells; antibody-drug conjugates (ADCs) deliver medicine directly to tumors.

What's Next for Whitehawk?

• Entered into an intellectual property license agreement with WuXi Biologics in December 2024 for the development of three ADC therapies.
• Divested the FYARRO business to KAKEN INVESTMENTS INC. in March 2025 for $102.4 million to focus on the newer ADC portfolio.
• Established an option agreement with Hangzhou DAC in May 2026 for access to core technology for up to five additional programs.
• Started a global collaboration with Biocytogen in June 2026 to develop bispecific antibody-drug conjugates that bind to two targets at once.

What Makes Whitehawk Different?

The company uses a specialized linker-payload platform called CPT113 that remains stable in the blood until it reaches cancer cells. This technology allows for the targeted release of medicine at the tumor site while reducing side effects in the rest of the body.

A Look at the Numbers

• Cash, cash equivalents, and short-term investments totaled $190.0 million as of June 30, 2026.
• Net loss was $38.8 million for the six-month period ended June 30, 2026.
• Raised $81.8 million in net proceeds through a private investment in public equity financing in May 2026.
• Market capitalization was $210.2 million as of the current profile report.
• Product sales, net were $0 for the six-month period ended June 30, 2026, following the sale of the commercial business.

Bottom Line

Whitehawk has shifted from selling a specific medicine to developing a pipeline of new, highly targeted cancer treatments. Its focus on advanced antibody-drug conjugates and recent fundraising support its transition into a clinical-stage research company.